Core Insights - NeOnc Technologies Holdings, Inc. has appointed Dr. David M. Ashley to its scientific advisory board, enhancing its expertise in neuro-oncology [2][3] - Dr. Ashley is recognized for his significant contributions to brain tumor immunology and epigenetics, which will strengthen NeOnc's clinical pipeline, particularly its lead candidates NEO100™ and NEO212™ [3][4] - NeOnc is focused on developing therapies for central nervous system cancers, with its NEO™ drug development platform producing novel drug candidates that have shown positive effects in laboratory tests and clinical trials [5] Company Overview - NeOnc Technologies is a clinical-stage biopharmaceutical company specializing in central nervous system therapeutics, addressing challenges related to the blood-brain barrier [5] - The company’s lead candidates, NEO100™ and NEO212™, are currently in Phase II human clinical trials and have received FDA Fast-Track and Investigational New Drug (IND) status [5] - NeOnc holds an extensive worldwide patent portfolio licensed from the University of Southern California, covering various uses for its products, including oncological and neurological conditions [5]